| Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system Y Zhou, KA Gammeltoft, LA Ryberg, LV Pham, HD Tjørnelund, A Binderup, ... Science Advances 8 (51), eadd7197, 2022 | 114 | 2022 |
| In vitro efficacy of artemisinin-based treatments against SARS-CoV-2 Y Zhou, K Gilmore, S Ramirez, E Settels, KA Gammeltoft, LV Pham, ... Scientific Reports 11 (1), 14571, 2021 | 90 | 2021 |
| Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro KA Gammeltoft, Y Zhou, CR Duarte Hernandez, A Galli, A Offersgaard, ... Antimicrobial Agents and Chemotherapy 65 (9), 10.1128/aac. 02680-20, 2021 | 39 | 2021 |
| Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine K Lothert, AF Offersgaard, AF Pihl, CK Mathiesen, TB Jensen, GP Alzua, ... Scientific Reports 10 (1), 16261, 2020 | 31 | 2020 |
| SARS-CoV-2 production in a scalable high cell density bioreactor A Offersgaard, CR Duarte Hernandez, AF Pihl, R Costa, NP Venkatesan, ... Vaccines 9 (7), 706, 2021 | 20 | 2021 |
| Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro Y Zhou, KA Gammeltoft, A Galli, A Offersgaard, U Fahnøe, S Ramirez, ... Viruses 13 (10), 2082, 2021 | 19 | 2021 |
| Specific antibodies induced by immunization with hepatitis B virus-like particles carrying hepatitis C virus envelope glycoprotein 2 epitopes show differential neutralization … A Czarnota, A Offersgaard, AF Pihl, J Prentoe, J Bukh, JM Gottwein, ... Vaccines 8 (2), 294, 2020 | 18 | 2020 |
| Hepatitis C virus RNA is 5′-capped with flavin adenine dinucleotide AV Sherwood, LR Rivera-Rangel, LA Ryberg, HS Larsen, KM Anker, ... Nature 619 (7971), 811-818, 2023 | 14 | 2023 |
| High density Huh7. 5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals AF Pihl, AF Offersgaard, CK Mathiesen, J Prentoe, U Fahnøe, H Krarup, ... Scientific reports 8 (1), 17505, 2018 | 14 | 2018 |
| Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice AF Pihl, S Feng, A Offersgaard, GP Alzua, EH Augestad, CK Mathiesen, ... Journal of Hepatology 76 (5), 1051-1061, 2022 | 11 | 2022 |
| Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice GP Alzua, AF Pihl, A Offersgaard, CRD Hernandez, Z Duan, S Feng, ... Gut 72 (3), 560-572, 2023 | 9 | 2023 |
| Nirmatrelvirresistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci Adv 8: eadd7197 Y Zhou, KA Gammeltoft, LA Ryberg, LV Pham, HD Tjørnelund, A Binderup, ... Inhibitor A (patient is resistant), 2022 | 6 | 2022 |
| Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in vitro. bioRxiv Y Zhou, KA Gammeltoft, LA Ryberg, LV Pham, U Fahnøe, A Binderup, ... Preprint] 10 (2022.06), 06.494921, 2022 | 5 | 2022 |
| Toward a vaccine against hepatitis C virus A Offersgaard, J Bukh, JM Gottwein Science 380 (6640), 37-38, 2023 | 4 | 2023 |
| Identification of novel neutralizing determinants for protection against HCV GP Alzua, AF Pihl, A Offersgaard, R Velázquez‐Moctezuma, ... Hepatology 77 (3), 982-996, 2023 | 4 | 2023 |
| High-Titer hepatitis C virus production in a scalable single-use high cell density bioreactor A Offersgaard, CR Duarte Hernandez, AF Pihl, NP Venkatesan, H Krarup, ... Vaccines 10 (2), 249, 2022 | 2 | 2022 |
| Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir KA Gammeltoft, Y Zhou, LA Ryberg, LV Pham, A Binderup, ... Viruses 15 (9), 1970, 2023 | 1 | 2023 |
| Effect of Glycan Shift on Antibodies against Hepatitis C Virus E2 412–425 Epitope Elicited by Chimeric sHBsAg-Based Virus-Like Particles A Czarnota, A Offersgaard, A Owsianka, GP Alzua, J Bukh, JM Gottwein, ... Microbiology spectrum 11 (2), e02546-22, 2023 | 1 | 2023 |
| An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals A Offersgaard, CRD Hernandez, S Feng, P Marichal-Gallardo, ... Iscience 26 (2), 2023 | 1 | 2023 |
| Method of purifying whole virus particles JM Gottwein, J Bukh, A Offersgaard, AF Pihl, M Wolff, K Lothert US Patent App. 18/016,150, 2023 | | 2023 |
